PAP
ASND icon

Persistent Asset Partners’s Ascendis Pharma A/S ASND Stock Holding History

Persistent Asset Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.1K Buy
+237
New +$53.1K 0.01% 273

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Persistent Asset Partners's ASND Position: Q1 2026 in Review

Persistent Asset Partners sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 1,832 shares — an estimated $411K sold.

Persistent Asset Partners first reported a position in ASND in Q4 2024 and held it in 4 quarters. The position peaked at $1.26M in Q3 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Persistent Asset Partners reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 1,832 Ascendis Pharma A/S shares in Q1 2026, an estimated $411K.
  • Persistent Asset Partners first reported a position in Ascendis Pharma A/S in Q4 2024 and held it in 4 quarters.
  • Persistent Asset Partners's Ascendis Pharma A/S position peaked at $1.26M in Q3 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.